GlassScriptPhysician profile
Sarabjit Bhalla
NPI 1356337968
$1,468.19
in general payments reported to CMS, 2019-2025
24 companies · $571 in 2025
The $571 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.98 · 2021: $123 · 2022: $193 · 2023: $231 · 2024: $266 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.07 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $154.11 | 2023-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $126.78 | 2021-2024 | Farxiga |
| Amgen INC. | $117.43 | 2019-2025 | Tavneos |
| Horizon Therapeutics Plc | $112.58 | 2022-2023 | Krystexxa |
| Vantive US Healthcare LLC | $104.90 | 2025 | |
| Akebia Therapeutics INC | $102.21 | 2022-2025 | Vafseo |
| Glaxosmithkline, LLC. | $93.71 | 2021-2025 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $84.93 | 2023-2025 | |
| Travere Therapeutics, INC. | $77.66 | 2024-2025 | |
| Ardelyx, INC. | $62.23 | 2023-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $59.28 | 2019-2023 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.24 | 2021-2025 | Jardiance |
| Daiichi Sankyo INC. | $41.09 | 2019-2021 | |
| Veloxis Pharmaceuticals, INC. | $37.77 | 2024 | Envarsus |
| Aurinia Pharma U.S., INC. | $35.58 | 2021-2023 | Lupkynis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $28.80 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.16 | 2025 | |
| Ani Pharmaceuticals, INC. | $25.69 | 2022 | |
| Vifor Pharma, INC. | $24.79 | 2025 | Veltassa |
| Calliditas Therapeutics US INC. | $24.00 | 2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $22.36 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.70 | 2022 | |
| Genzyme Corporation | $15.91 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarabjit Bhalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.